Drug Trial Radar · NCT01616303
A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Sep 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
97
Actual
Start
Jun 15, 2012
Primary completion
Jun 15, 2015
Study completion Oct 12, 2018
Sponsor
- Lead sponsor
- Quest PharmaTech Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 11, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2 randomized study with two treatment arms to compare the effectiveness of oregovomab (a murine monoclonal antibody directed against cancer antigen 125 (CA125)) when combined with first-line chemotherapy (carboplatin and paclitaxel) to first-line chemotherapy (carboplatin and paclitaxel alone) in female patients with advanced ovarian cancer.
Conditions
- Ovarian Neoplasms
Interventions
CarboplatinDrug
carboplatin (area under the curve (AUC) 6, administered intravenously in a single day for 6 cycles every three weeks \[21 days\])
PaclitaxelDrug
Paclitaxel (175 mg / square meter, intravenously over three hours in one day to be repeated for 6 cycles every three weeks \[21 days\])
oregovomabBiological
oregovomab (2 mg infused intravenously jointly during the 1st, 3rd and 5th chemotherapy cycle and 12 weeks after the 5th cycle).
Primary outcomes
What the sponsor says the trial is designed to measure.
- CA125 ELISPOT assay response for cytotoxic T cell antigen specific immunity induction to end of first-line chemotherapyTime frame: At Baseline (up to 4 weeks before Cycle 1), at Cycle 5 (approximately 12 weeks after Cycle 1) and termination (approximately 25 weeks after Cycle 1)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University of Connecticut Health Center
Farmington, Connecticut
Northern Indiana Cancer Research Consortium
South Bend, Indiana
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.